Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501)
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background: Left thoracic approach (LTA) has been a favorable selection in surgical treatment for esophageal cancer (EC) patients in China before minimally invasive esophagectomy (MIE) is popular. This study aimed to demonstrate whether right thoracic approach (RTA) is superior to LTA in the surgical treatment of middle and lower thoracic esophageal squamous cell carcinoma (TESCC). Methods: Superiority clinical trial design was used for this multicenter randomized controlled two-parallel group study. Between April 2015 and December 2018, cT1b-3N0-1M0 TESCC patients from 14 centers were recruited and randomized by a central stratified block randomization program into LTA or RTA groups. All enrolled patients were followed up every three months after surgery. The software SPSS 20.0 and R 3.6.2. were used for statistical analysis. Efficacy and safety outcomes, 3-year overall survival (OS) and disease-free survival (DFS) were calculated and compared using the Kaplan-Meier method and the log-rank test. Results: A total of 861 patients without suspected upper mediastinal lymph nodes (umLN) were finally enrolled in the study after 95 ineligible patients were excluded. 833 cases (98.7%) were successfully followed up until June 1, 2020. Esophagectomies were performed via LTA in 453 cases, and via RTA in 408 cases. Compared with the LTA group, the RTA group required longer operating time (274.48±78.92 vs. 205.34±51.47 min, P<0.001); had more complications (33.8% vs. 26.3% P=0.016); harvested more lymph nodes (LNs) (23.61±10.09 vs. 21.92±10.26, P=0.015); achieved a significantly improved OS in stage IIIa patients (67.8% vs. 51.8%, P=0.022). The 3-year OS and DFS were 68.7% and 64.3% in LTA arm versus 71.3% and 63.7% in RTA arm (P=0.20; P=0.96). Conclusions: Esophagectomies via both LTA and RTA can achieve similar outcomes in middle or lower TESCC patients without suspected umLN. RTA is superior to LTA and recommended for the surgical treatment of more advanced stage TESCC due to more complete lymphadenectomy. Trial Registration: ClinicalTrials.gov NCT02448979.
Source: Annals of Translational Medicine
DOI: 10.21037/atm-22-3810
Authors: You-Sheng Mao, Shu-Geng Gao, Yin Li, An-Lin Hao, Jun-Feng Liu, Xiao-Fei Li, Tie-Hua Rong, Jian-Hua Fu, Jian-Qun Ma, Mei-Qing Xu, Ren-Quan Zhang, Gao-Ming Xiao, Xiang-Ning Fu, Ke-Neng Chen, Wei-Min Mao, Yong-Yu Liu, Hong-Xu Liu, Zhi-Rong Zhang, Yan Fang, Dong-Hong Fu, Xu-Dong Wei, Li-Gong Yuan, Shan Muhammad, Wen-Qiang Wei, Philip Wai-Yan Chiu, Shane Lloyd, Francisco Schlottmann, Kenneth Meredith, Jose M. Pimiento, Yi-Bo Gao, Jie He
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Henan Cancer Hospital, Anyang Tumor Hospital, Fourth Hospital of Hebei Medical University, Air Force Medical University, Sun Yat-sen University Cancer Center, Anhui Provincial Hospital, Anhui Medical University, First Affiliated Hospital of Anhui Medical University, Hunan Cancer Hospital, Tongji University, Tongji Hospital, Peking University, Peking University Cancer Hospital, Zhejiang Cancer Hospital, Liaoning Cancer Hospital & Institute, Chinese University of Hong Kong, Prince of Wales Hospital, University of Utah, Huntsman Cancer Institute, University of Illinois Chicago, Hospital Alemán, Sarasota Memorial Health Care System, Sarasota Memorial Hospital, Moffitt Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4293692018